CClinicalTrials.gg
RecruitingNCT03256240Updated May 14, 2026

Study of the Kono-S Anastomosis Versus the Side-to-side Functional End Anastomosis

An interventional study of side-to-side functional end anastomosis and Kono-S analstomosis in Crohn's Disease, sponsored by Weill Medical College of Cornell University. Recruiting at 15 sites in 6 countries. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-05-14.

Sponsored by Weill Medical College of Cornell University · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Study summary

This study proposes a randomized prospective study comparing the Kono-S anastomosis to the standard side-to-side anastomosis.This will be a multi-center randomized prospective trial. Patients with Crohn's ileitis or Crohn's ileocolitis requiring resection will be randomized to undergo either the Kono-S anastomosis or the side-to-side functional end anastomosis.

Read the detailed description

Study Aim:

  • The primary aim of this study is to compare the postoperative recurrence of CD using the modified Rutgeerts score at 3-6 months between the novel Kono-S anastomosis (Group1) and side-to-side functional end anastomosis (Group2) and surgical recurrence rate at 60 and 120 months between the groups. Evaluate histologic features in surgical specimen collected at the index surgery as predictors for endoscopic, clinical, and surgical recurrence after ileocecal resection for CD. To evaluate the histological mucosal healing at 60 months between the novel Kono-S anastomosis (Group1) and side-to-side functional end anastomosis (Group2) using Global Histology Activity Score and The Inflammatory Bowel Disease-Distribution, Chronicity, Activity [IBD-DCA] score.
  • The secondary aim is to evaluate the postoperative endoscopic recurrence of CD using the modified Rutgeerts score at 12-18, 60 and 120 months between the groups; time to surgical recurrence between Group1 and Group2 measured in months from the index surgery; yearly Crohn's disease surgical therapy impact using the Work Productivity and Activity Impairment (WPAI) questionnaire; yearly Health-Related Quality of Life using the Short Inflammatory Bowel Disease Questionnaire; to evaluate before surgery, and yearly after the surgery up 60 months the patient perception of illness measured by The Brief Illness Perception Questionnaire, (a 9-item questionnaire) score between the groups, to evaluate disease activity yearly using Harvey-Bradshaw Index, and monitor medication therapy, anastomotic strictures, readmission rates, and mortality rates through the 120 months follow-up, and utilize Focus Groups from national and international study sites to evaluate patient's perspectives on surgical treatment, patients' goals of surgical treatment, and surgical treatment's personal and social impacts, patient perspective on nutrition; and long-term psychosocial impact and nutrition challenges, and to evaluate the differences in the histological/mucosal healing between Kono-S and Side-to-Side anastomoses.

Methods

Design: This will be a multi-center randomized prospective trial with 500 subjects. Patients with Crohn's ileitis or Crohn's ileocolitis requiring initial resection will be randomized to undergo either the Kono-S anastomosis or the side-to-side functional end anastomosis.

Patients will be randomized into two Groups:

Group 1: Kono-S anastomosis vs. Group 2: side-to-side functional end anastomosis (control group).

The purpose of this study is to compare the postoperative recurrence of Crohn's disease between the Kono-S procedure and the side-to-side functional end anastomosis and to evaluate the surgical recurrence rate at 60 and 120 months between the groups.

In any intestine surgery, after the sick portion of the bowel is removed, the intestinal tract is restored by reconnecting the healthy ends together. The new connecting line is called anastomosis and could be created in a variety of ways by the surgeon. This study will compare two different intestinal connections called Kono-S anastomosis and the traditional side-to-side functional end anastomosis. Initial studies have demonstrated that the Kono-S anastomosis has prevented endoscopic evidence of the post-operative recurrence of Crohn's disease at greater rates than the traditional side-to-side functional end anastomosis.

Follow-up: Patients will be discharged on no prophylactic treatments, and they will be followed post-operatively at 3 to 6, 12 to 18, 60-, and 120 months with a colonoscopy to assess for endoscopic recurrence. The mucosa will be graded with the modified Rutgeerts score for postoperative recurrence. All colonoscopies are part of the standard treatment. All patients will have also standard 30 days, 3 to 6, 12 to 18, 24, 36-, 48-, 60-, 72-, 84-, 96-, 108-, and 120 months follow-ups by phone call, through medical records, or during the postoperative clinic visit.

Follow-up Care: Patients with a Rutgeerts score at 3-to-6 months of:

  • All participating sites follow the same endoscopic evaluation protocol at 3-6, 12-18, 60, and 120 months, using the modified Rutgeerts score for grading the endoscopic recurrence
  • 0, 1, or 2a will be followed prospectively with or without introducing medical treatment at the discretion of the gastroenterologist.
  • above >2a will initiate medical therapy for Crohn's disease at the discretion of the gastroenterologist.
  • Should the patient's symptoms warrant, medical treatment can be initiated at any time at the discretion of the gastroenterologist. This is a standard of care
  • 3 Colonoscopic images (still color photos acceptable) are taken to ensure standardized evaluation of the anastomoses and will be shown to a gastroenterologist blinded to the goal of the study for determination of the Rutgeerts score in addition to the initial evaluation by the sites endoscopists, and for additional analyses.
  • post-operative endoscopic recurrence of CD using the modified Rutgeerts score at 12-18-, 60-, and 120 months between the groups. An endoscopic Rutgeerts score of 2b or higher will be considered a recurrence.
  • Time to surgical recurrence between Group1 and Group2 measured in months from the index surgery
  • Work Productivity and Activity Impairment (WPAI) questionnaire (a 6-item questionnaire that measures the amount of absenteeism and presenteeism due to health problems) will be administered annually for up to 120 months.
  • Health-Related Quality of Life using the Short Inflammatory Bowel Disease Questionnaire (SIBDQ) (a 10-item shortened version of the original IBDQ, measuring the quality of life in four domains: bowel symptoms, emotional health, systemic systems, and social function) will be administered annually for up to 120 months.
  • The Brief Illness Perception Questionnaire, (a 9-item questionnaire) score measuring the patient perception of illness before surgery, at 24-, 36-, 48-, 60-, 72-, 84-, 96-, 108-, and 120-months post-procedure.
  • Harvey Bradshaw Index as a marker of clinical disease activity will be used. This will be recorded before the procedure (baseline), at 3 to 6 and 12-18 months, 24-, 36-, 48-, 60-, 72-, 84-, 96-, 108-, and 120-months post-procedure.
  • Other monitoring- monitor medication therapy, readmission rates, postoperative morbidity and mortality rates annually through the 120 months of follow-up between the groups
  • Focus groups from national and international study sites to evaluate patients' perspectives on surgical treatment, patients' goals of surgical treatment, and surgical treatment's personal and social impacts, patient perspective on nutrition; and long-term psychosocial impact and nutrition challenges. This is a qualitative evaluation.
  • surgical pathology margin evaluation will be used to assess for histologic predictors for endoscopic and clinical remission in Crohn's Disease after ileocecal resection
  • The differences in the histological mucosal healing between Kono-S and Side- to Side anastomosis measured by the histological score between the groups using the modified Global Histology Activity Score (Modified) between the groups at 60 months.
02

Conditions studied

  • Crohn's Disease

Browse trials for

Keywords

  • Crohn's recurrence
03

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Patients with Crohn's ileitis or ileocolitis requiring initial surgical resection.
  2. Age of 18 years and older, male and female
  3. All Phenotypes of Crohn's diisease will be included: nonpenetrating (B1), stricturing (B2), and penetrating (fistulating) (B3), according to the Vienna classification
  4. The patients can be on any medications coming into surgery, including prior anti- tumor necrosis factor(TNF) therapy.

Exclusion criteria

Exclusion Criteria:

  1. Patients under 18 years of age
  2. Patients with recurrent Crohn's
  3. Pregnant patients
  4. Patients with more than one non-contiguous site of active disease, thus requiring multiple resections or additional bowel sparing procedures at the time of surgery.
  5. Patients with Crohn's disease extending to the cecum and ascending colon
  6. Patients who will need preventive postoperative medical treatment
  7. Patients that need change of surgical procedure as per the surgeon at the time of the intraoperative abdominal evaluation.
04

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
600 participants (estimated)

Study arms

  • Active comparator
    side-to-side functional end anastomosis

    side-to-side functional end anastomosis creation

    Other: side-to-side functional end anastomosis

  • Active comparator
    Kono-S

    antimesenteric functional side-to-side handsewn anastomosis, known as the Kono-S anastomosis

    Other: Kono-S analstomosis

Interventions

  • Otherside-to-side functional end anastomosis

    type of anastomosis

  • OtherKono-S analstomosis

    antimesenteric anastomosis

05

What researchers measure

Primary outcomes

  1. Post-operative endoscopic remission of Crohn's disease between 3 and 6 months after surgery

    Endoscopic remission with a modified Rutgeerts score between 3 and 6 months in order to determine if the Kono-S procedure is more likely to prevent post-operative recurrence of Crohn's disease compared with the side-to-side functional end anastomosis. Endoscopic remission is defined as a modified Rutgeerts score of 0, 1, or 2a at 3-to-6 months post-procedure colonoscopy.

    Time frame: 3-6 months after surgery

  2. Number of subjects with surgical recurrence at 60 months

    Number of anastomoses in need of surgical revision for Crohn's disease recurrence after the initial index surgery.

    Time frame: 60 months after surgery

  3. Number of subjects with surgical recurrence at 120 months

    Number of anastomoses in need of surgical revision for Crohn's disease recurrence after the initial index surgery.

    Time frame: 120 months after surgery

  4. Mucosal Healing GHS

    Mucosal Healing from colonoscopy biopsies using the modified Global Histology Activity Score (Modified) score between the groups. Global Histology Activity Score (GHAS) is a widely used tool that grades biopsies of the ileum and colonic segments. The score has 8 domains and includes the presence of architectural changes, degree of chronic, neutrophilic and eosinophilic inflammatory infiltration in lamina propria, presence of intraepithelial neutrophils, epithelial damage, mucosal defects, presence of granulomas, and the extent of inflammation (proportion of biopsy specimens affected). Each domain is scored independently, and the total score is the sum of all individual scores, ranging from 2 (being the lowest meaning no histological activity) to 16 (being the highest meaning high histological disease activity).

    Time frame: 60 months after surgery

  5. Mucosal Healing IBD-DCA

    Mucosal Healing from colonoscopy biopsies using The Inflammatory Bowel Disease-Distribution, Chronicity, Activity \[IBD-DCA\] score between the groups. The score is validated and has 3 domains: 1) Distribution of the disease; 2) Chronicity of the disease; and 3) Activity of the disease. Each domain of the IBD-DCA is scored as one of 0 (normal), 1 (mild), or 2 (moderate to severe) based on the presence of established histological findings and the domains are separately reported. Distribution \[D\] 0=Normal 1. \< 50% of tissue affected per same biopsy site 2. ≥ 50% of tissue affected per same biopsy site Chronic features \[C\] 0=Normal 1=Crypt distortion and/or mild lymphoplasmacytosis 2=Marked lymphoplasmacytosis and/or marked basal plasmacytosis Activity features \[A\] 0=Normal 1. Two or more neutrophils in lamina propria in one high-power field \[HPF\] and/or intraepithelial neutrophils \[any number\] 2. Crypt abscesses, erosions, ulcers

    Time frame: 60 months after surgery

  6. Surgical Pathology Margins

    Histological evaluation of the surgical pathology margin evaluation for presence or absence of disease

    Time frame: at surgery

Secondary outcomes

  1. Post-operative endoscopic remission of Crohn's disease between 12 and 18 months, at 60-, and 120 months after surgery

    Endoscopic remission with a modified Rutgeerts score at 12 to 18, 60-, and 120 months in order to determine if the Kono-S procedure is more likely to prevent post-operative recurrence of Crohn's disease compared with the side-to-side functional end anastomosis. An endoscopic Rutgeerts score of 2b or higher will be considered a recurrence.

    Time frame: 12-18, 60, and 120 months after surgery

  2. Work Productivity and Activity Impairment (WPAI) due to Crohn's disease

    Work Productivity and Activity Impairment (WPAI) is a validated 6-item questionnaire that measures the amount of absenteeism and presenteeism due to CD during and activity impairment the 7 days prior to administration. It consists of 6 questions with the following domains: 1) employment status; 2) hours missed due to CD; 3) hours missed due to other reasons; 4) hours actually worked; 5) the degree to which CD affected productivity while working from 0 (no effect) to 10 (maximum impairment); and 6) the degree to which CD affected regular activities from 0 (no effect) to 10 maximum impairment ). All six question' domains will be reported and compared between the groups. Between the groups and within patients, changes will be evaluated. The mean score annual variability in each domain will be evaluated.

    Time frame: up to 120 months

  3. Health-Related Quality of Life using the Short Inflammatory Bowel Disease Questionnaire for Crohn's disease(10 questions)

    Validated questionnaire to evaluate the quality of life in IBD patients. The short Inflammatory Bowel Disease Questionnaire (SIBDQ) is a 10-item shortened version of the original IBDQ, which was 32 items. Measures quality of life as measured in four domains, bowel symptoms, emotional health, systemic systems, and social function. SIBDQ score ranges between 10 and 70 points. QUOL is considered to be slightly (60-70 points), moderately (45-60 points), or severely impaired (10-45 points). In our study, the cut-off for relevant impairment of QUOL \< 60 points.

    Time frame: up to 120 months

  4. Clinical disease activity measured by Harvey Bradshaw Index

    Harvey Bradshaw Index is a marker of clinical disease activity. The following score grading system will be used to determine the clinical disease activity: Remission \< 5 Mild disease 5-7 Moderate disease 8-16 Severe disease \>16

    Time frame: up to 120 months

  5. Time to surgical recurrence between Group1 and Group2

    Time to surgical recurrence between Group1 and Group2 measured in months from the index surgery

    Time frame: up to 120 months

  6. Focus Group

    Patient Focus Groups from national and international study sites to evaluate patient's perspectives on surgical treatment, patients' goals of surgical treatment, and surgical treatment's personal and social impacts, patient perspective on nutrition, long-term psychosocial impact and nutrition challenges, and caregiver perspective on surgical treatment.

    Time frame: up to 120 months

  7. Medication therapy type

    Medication therapy for Crohn's disease after the index surgery. We will monitor the type of medications patients receive after surgery. The following five types of medications will be recorded: Biologics, Immunosuppressants, Corticosteroids, Anti-Inflammatory, and Antibiotics.

    Time frame: up to 120 months

  8. Readmission rates between Group1 and Group2

    Number of readmission due to Crohn's disease after the index surgery

    Time frame: up to 120 months

  9. Mortality rate

    Number of patient expired after the index surgery

    Time frame: up to 120 months

  10. The Brief Illness Perception Questionnaire

    The Brief Illness Perception Questionnaire, (a 9-item questionnaire) score with the nine items rated on a scale from 0 (minimum) to 10 (maximum), with higher scores indicating a more threatening perception of the illness. The total score is calculated by summing the scores of all eight items, with a possible range of 0-80. Higher scores indicate worse illness perception.

    Time frame: up to 120 months

  11. Postoperative Morbidity

    Postoperative morbidity is defined as any deviation from the normal postoperative recovery course occurring within 30 days after surgery, as documented in daily in-hospital checks, clinical documentation records, imaging, laboratory results, interventional notes, or surgeon assessment, and presented as a binary outcome- "Yes" or "No".

    Time frame: within 30 days after surgery

  12. Postoperative Morbidity

    Postoperative morbidity is defined as any deviation from the normal postoperative recovery course occurring up to 120 months after surgery, as documented in daily in-hospital checks, clinical documentation records, imaging, laboratory results, interventional notes, or surgeon assessment, and presented as a binary outcome- "Yes" or "No".

    Time frame: up to 120 months

06

Study locations

8 of 15 sites recruiting
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
    Terminated
  • Weill Cornell Medical College
    New York, New York 10065, United States
    Recruiting
  • University of Oklahoma
    Oklahoma City, Oklahoma 73112, United States
    Terminated
  • Baylor Scott & White Research Institute
    Dallas, Texas 75204, United States
    Terminated
  • Baylor College of Medicine
    Houston, Texas 77030, United States
    Terminated
  • University of Washington Medical Center
    Seattle, Washington 98195, United States
    Terminated
  • University Clinics Gasthuisberg Herestraat
    Leuven, 3000, Belgium
    Recruiting
  • Helsinki University Hospital
    Helsinki, Helsinki 00029, Finland
    Terminated
  • Universitätsklinik Würzburg
    Würzburg, Wurzburg D-97080, Germany
    • Sven Flemming, MD · Contact · Flemming_S@ukw.de
    • Sven Flemming, MD · Principal investigator
    Recruiting
  • Charité Campus Benjamin Franklin
    Berlin, 12203, Germany
    Recruiting
  • Theresien Hospital and St. Hedwigs Clinic gGmbH
    Mannheim, 68165, Germany
    Recruiting
  • Azienda Ospedaliero-Universitaria Careggi
    Florence, Florence 50134, Italy
    Recruiting
  • Humanitas University Hospital
    Rozzano, Milan 20089, Italy
    Recruiting
  • Policlinico University Hospital
    Naples, Italy
    Recruiting
  • Hospital Universitario Vall d'Hebron
    Barcelona, Barcelona 08035, Spain
    Terminated
07

References and documents

Publications

  • Kono T, Ashida T, Ebisawa Y, Chisato N, Okamoto K, Katsuno H, Maeda K, Fujiya M, Kohgo Y, Furukawa H. A new antimesenteric functional end-to-end handsewn anastomosis: surgical prevention of anastomotic recurrence in Crohn's disease. Dis Colon Rectum. 2011 May;54(5):586-92. doi: 10.1007/DCR.0b013e318208b90f. PubMed 21471760 ↗
  • Kono T, Fichera A. Kono-S anastomosis for Crohn's disease: narrative - a video vignette. Colorectal Dis. 2014 Oct;16(10):833. doi: 10.1111/codi.12722. No abstract available. PubMed 25040294 ↗
08

Registry details

Key details

Study ID
NCT03256240
Lead sponsor
Weill Medical College of Cornell University
Collaborators
Crohn's and Colitis Foundation, The Leona M. and Harry B. Helmsley Charitable Trust
Responsible party
Sponsor
First posted
Aug 21, 2017
Start date
Mar 12, 2014
Primary completion
Jul 31, 2030 (estimated)
Completion
Dec 31, 2036 (estimated)
Last update
May 14, 2026

Study contacts

Koianka Trencheva, Dr.PH,BSN,MS
Contact
kivanova@med.cornell.edu
646-962-2342
Fabrizio Michelassi, MD
principal investigator · Weill Medical College of Cornell University
Koianka Trencheva, Dr.PH,BSN,MS
principal investigator · Weill Medical College of Cornell University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion